Aquinox Pharmaceuticals (AQXP) Upgraded by BidaskClub to Hold
BidaskClub upgraded shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from a sell rating to a hold rating in a research note published on Wednesday morning.
A number of other brokerages have also issued reports on AQXP. Guggenheim started coverage on Aquinox Pharmaceuticals in a report on Thursday, February 8th. They issued a buy rating and a $26.00 price objective for the company. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the stock a buy rating in a report on Monday, December 11th. Zacks Investment Research raised Aquinox Pharmaceuticals from a hold rating to a buy rating and set a $13.00 price objective for the company in a report on Tuesday, January 9th. Cantor Fitzgerald reissued a buy rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a report on Sunday. Finally, Needham & Company LLC reissued a buy rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $22.80.
Shares of Aquinox Pharmaceuticals (AQXP) traded up $0.25 during mid-day trading on Wednesday, reaching $16.25. The company had a trading volume of 205,600 shares, compared to its average volume of 118,005. Aquinox Pharmaceuticals has a 1-year low of $10.02 and a 1-year high of $19.35. The company has a market cap of $375.44, a price-to-earnings ratio of -8.42 and a beta of -15.98.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.